Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?

References

• BakerMALinHHChangHYMurrayMBThe risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort studyClin Infect Dis2012546 818 82522238171
   PubMed Web of Science ®Google Scholar
• JeonCYMurrayMBBakerMAManaging tuberculosis in patients with diabetes mellitus: why we care and what we knowExpert Rev Anti Infect Ther2012108 863 86823030325
   PubMed Web of Science ®Google Scholar
• Jiménez-CoronaMECruz-HervertLPGarcía-GarcíaLAssociation of diabetes and tuberculosis: impact on treatment and post-treatment outcomesThorax2013683 214 22023250998
   PubMed Web of Science ®Google Scholar
• AlisjahbanaBSahiratmadjaENelwanEJThe effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosisClin Infect Dis2007454 428 43517638189
   PubMed Web of Science ®Google Scholar
• StevensonCRForouhiNGRoglicGDiabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidenceBMC Public Health20077 23417822539
   PubMed Web of Science ®Google Scholar
• LönnrothKRoglicGHarriesADImproving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practiceLancet Diabetes Endocrinol201429 730 73925194886
   PubMed Web of Science ®Google Scholar
• LeeMRHuangYPKuoYTDiabetes mellitus and latent tuberculosis infection: a systemic review and metaanalysisClin Infect Dis2017646 719 72727986673
   PubMed Web of Science ®Google Scholar
• ZumlaAIGillespieSHHoelscherMNew antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospectsLancet Inf Dis2014144 327 340
   PubMed Web of Science ®Google Scholar
• DostalekMAkhlaghiFPuzanovovaMEffect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugsClin Pharmacokinet2012518 481 49922668340
   PubMed Web of Science ®Google Scholar
• CasqueiroJCasqueiroJAlvesCInfections in patients with diabetes mellitus: a review of pathogenesisIndian J Endocrinol Metab201216Suppl 1 S27 S3622701840
   PubMedGoogle Scholar
• RestrepoBIDiabetes and tuberculosisMicrobiol Spectr201646 TNM17-0023-2016
   PubMed Web of Science ®Google Scholar
• Isoniazid^® (isoniazid) tablets [prescribing information]LondonAuden Mekenzie Limited2010
   Google Scholar
• Rifadin^® (rifampicin) hard capsules [prescribing information]GuildfordAventis Pharma Limited2005
   Google Scholar
• Sirturo^® (bedaquiline) tablets [prescribing information]BeerseJanssen-Cilag Int. N.V2012
   Google Scholar
• Deltyba^® (delamanid) film-coated tablets [prescribing information]MunchenOtsuka Novel Products GmbH2014
   Google Scholar
• GualanoGCaponeSMatteelliAPalmieriFNew antituberculosis drugs: from clinical trial to programmatic useInfect Dis Rep201682 656927403268
   PubMedGoogle Scholar
• D’AmbrosioLCentisRSotgiuGPontaliESpanevelloAMiglioriGBNew anti-tuberculosis drugs and regimens: 2015 updateERJ Open Res201511 00010 201527730131
   PubMedGoogle Scholar
• Priftin^® (rifapentine) tablets [prescribing information]Bridgewater, NJSanofi-Aventis U.S. LLC1998
   Google Scholar
• WHOGuidelines on the management of latent tuberculosis infection2015 Available from: http://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdfAccessed May 6, 2017
   Google Scholar
• HuangYMZhaoQPRenQMPengDLGuoYThe production and sales of anti-tuberculosis drugs in ChinaInfect Dis Poverty201651 8827716386
   PubMed Web of Science ®Google Scholar
• ChoSKYoonJSLeeMGRifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participantsClin Pharmacol Ther2011893 416 42121270793
   PubMed Web of Science ®Google Scholar
• NiemiMBackmanJTNeuvonenMNeuvonenPJEffect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjectsBr J Clin Pharmacol2003564 427 43212968988
   PubMed Web of Science ®Google Scholar
• NiemiMBackmanJTNeuvonenMNeuvonenPJKivistöKTEffects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizideClin Pharmacol Ther2001696 400 40611406737
   PubMed Web of Science ®Google Scholar
• LeowMKDalanRCheeCBLatent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implicationsExp Clin Endocrinol Diabetes20141229 528 53225003362
   PubMed Web of Science ®Google Scholar
• Drugbank.ca [homepage on the Internet]DrugBank: Rifapentine Available from: https://www.drugbank.ca/drugs/DB01201#pharmacologyAccessed May 7, 2017
   Google Scholar
• BoereeMJDiaconAHDawsonRPanACEA ConsortiumA dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisAm J Respir Crit Care Med20151919 1058 106525654354
   PubMed Web of Science ®Google Scholar
• SavicRMLuYBliven-SizemoreEPopulation pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailabilityAntimicrob Agents Chemother2014586 3035 304224614383
   PubMed Web of Science ®Google Scholar
• SavicRMWeinerMMacKenzieWRTuberculosis Trials Consortium of the Centers for Disease Control and PreventionDefining the optimal dose of rifapentine for pulmonary tuberculosis: exposure–response relations from two phase II clinical trialsClin Pharmacol Ther20171022 321 33128124478
   PubMed Web of Science ®Google Scholar
• Drugbank.ca [homepage on the Internet]DrugBank: Rifampicin Available from: https://www.drugbank.ca/drugs/DB01045Accessed May 7, 2017
   Google Scholar
• NijlandHMRuslamiRStalenhoefJEExposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetesClin Infect Dis2006437 848 85416941365
   PubMed Web of Science ®Google Scholar
• WeinerMEgelundEFEngleMPharmacokinetic interaction of rifapentine and raltegravir in healthy volunteersJ Antimicrob Chemother2014694 1079 108524343893
   PubMed Web of Science ®Google Scholar
• TempleMENahataMCRifapentine: its role in the treatment of tuberculosisAnn Pharmacother19993311 1203 121010573321
   PubMed Web of Science ®Google Scholar
• PodanyATBaoYSwindellsSAIDS Clinical Trials Group A5279 Study TeamEfavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis preventionClin Infect Dis2015618 1322 132726082504
   PubMed Web of Science ®Google Scholar
• SvenssonEMMurraySKarlssonMODooleyKERifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drugJ Antimicrob Chemother2015704 1106 111425535219
   PubMed Web of Science ®Google Scholar
• DooleyKEBliven-SizemoreEEWeinerMSafety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteersClin Pharmacol Ther2012915 881 88822472995
   PubMed Web of Science ®Google Scholar
• HolsteinABeilWOral antidiabetic drug metabolism: pharmacogenomics and drug interactionsExpert Opin Drug Metab Toxicol200953 225 24119331589
   PubMed Web of Science ®Google Scholar
• ZhengHXHuangYFrassettoLABenetLZElucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effect of enzyme induction and transporter inhibition for a drug and its primary metaboliteClin Pharmacol Ther2009851 78 8518843263
   PubMed Web of Science ®Google Scholar
• LinJHYamazakiMRole of P-glycoprotein in pharmacokinetics: clinical implicationsClin Pharmacokinet2003421 59 9812489979
   PubMed Web of Science ®Google Scholar
• RentonKWCytochrome P450 regulation and drug biotransformation during inflammation and infectionCurr Drug Metab200453 235 24315180493
   PubMed Web of Science ®Google Scholar
• AitkenAERichardsonTAMorganETRegulation of drug-metabolizing enzymes and transporters in inflammationAnnu Rev Pharmacol Toxicol200646 123 14916402901
   PubMed Web of Science ®Google Scholar
• XuDXWangJPSunMFChenYHWeiWLipopolysaccharide downregulates the expressions of intestinal pregnane x receptor and cytochrome p450 3a11Eur J Pharmacol20065361–2 162 17016556443
   PubMed Web of Science ®Google Scholar
• CameronARMorrisonVLLevinDAnti-inflammatory effects of metformin irrespective of diabetes statusCirc Res20161195 652 66527418629
   PubMed Web of Science ®Google Scholar
• Drugbank.ca [homepage on the Internet]DrugBank: Metformin Available from: https://www.drugbank.ca/drugs/DB00331Accessed May 9, 2017
   Google Scholar
• WilliamsonBDooleyKEZhangYBackDJOwenAInduction of influx and efflux transporters and cytochrome p450 3a4 in primary human hepatocytes by rifampin, rifabutin, and rifapentineAntimicrob Agents Chemother20135712 6366 636924060875
   PubMed Web of Science ®Google Scholar
• NiaziAKKalraSDiabetes and tuberculosis: a review of the role of optimal glycemic controlJ Diabetes Metab Disord2012111 2823497638
   PubMedGoogle Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract2009156 540 55919858063
   PubMed Web of Science ®Google Scholar
• DuckworthWCKitabchiAEInsulin metabolism and degradationEndocr Rev198122 210 2337028472
   PubMed Web of Science ®Google Scholar
• FerranniniEWahrenJFaberOKFeligPBinderCDeFronzoRASplanchnic and renal metabolism of insulin in human subjects: a dose-response studyAm J Physiol19832446 E517 E5276344651
   PubMed Web of Science ®Google Scholar
• RabkinRRyanMPDuckworthWCThe renal metabolism of insulinDiabetologia1984273 351 3576389240
   PubMed Web of Science ®Google Scholar
• RabkinRSimonNMSteinerSColwellJAEffect of renal disease on renal uptake and excretion of insulin in manN Engl J Med19702824 182 1875409813
   PubMed Web of Science ®Google Scholar
• EvansMSchumm-DraegerPMVoraJKingABA review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitationsDiabetes Obes Metab2011138 677 68421410860
   PubMed Web of Science ®Google Scholar
• Humalog^® (insulin lispro) injection [prescribing information]Indianapolis, INEli Lilly and Company2011
   Google Scholar
• NovoLog^® (insulin aspart) injection [prescribing information]Princeton, NJNovo Nordisk Inc2011
   Google Scholar
• Apidra^® (insulin glulisine) injection [prescribing information]Bridgewater, NJSanofi-Aventis2009
   Google Scholar
• Lantus^® (insulin glargine) injection [prescribing information]Bridgewater, NJSanofi-Aventis2007
   Google Scholar
• Levemir^® (insulin detemir) injection [prescribing information]Bagsvaerd, DenmarkNovo Nordisk Inc2015
   Google Scholar
• Tresiba^® (insulin degludec) injection [prescribing information]Bagsvaerd, DenmarkNovo Nordisk Inc2013
   Google Scholar
• Saxenda^® (liraglutide) injection [prescribing information]Bagsvaerd, DenmarkNovo Nordisk Inc2015
   Google Scholar
• SymlinPen^® (pramlintide acetate) injection [prescribing information]LondonAstraZeneca2015
   Google Scholar
• Bemer-MelchiorPBryskierADrugeonHBComparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complexJ Antimicrob Chemother2000464 571 57611020254
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet20043649435 685 69615325833
   PubMed Web of Science ®Google Scholar
• SkottheimIBGedde-DahlAHejazifarSHoelKAsbergAStatin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitroEur J Pharm Sci2008334–5 317 32518294823
   PubMed Web of Science ®Google Scholar
• MarquesMPCoelhoEBDos SantosNAGeleileteTJLanchoteVLDynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitusEur J Clin Pharmacol2002589 607 61412483453
   PubMed Web of Science ®Google Scholar
• WilliamsDLSpringLCollinsLContribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosisAntimicrob Agents Chemother1998427 1853 18579661035
   PubMed Web of Science ®Google Scholar
• DuanmuHJLiuYHJiangGLWangSMFuYHIn vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosisZhonghua Jie He He Hu Xi Za Zhi2005283 192 19415854417
   PubMedGoogle Scholar
• CorazzaGRFrazzoniMGattoMRGasbarriniGAgeing and small-bowel mucosa: a morphometric studyGerontology1986321 60 65
   PubMed Web of Science ®Google Scholar
• FülöpTJrWórumICsongorJFórisGLeöveyABody composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjectsGerontology1985311 6 143972257
   PubMed Web of Science ®Google Scholar
• KeungACEllerMGWeirSJSingle-dose pharmacokinetics of rifapentine in elderly menPharm Res1998158 1286 12919706063
   PubMed Web of Science ®Google Scholar
• CadeWTDiabetes-related microvascular and macrovascular diseases in the physical therapy settingPhys Ther20088811 1322 133518801863
   PubMed Web of Science ®Google Scholar
• WooJLeungAChanKLaiKNTeohRPyrazinamide and rifampicin regimens for patients on maintenance dialysisInt J Artif Organs1988113 181 1853403055
   PubMed Web of Science ®Google Scholar
• MaloneRSFishDNSpiegelDMChildsJMPeloquinCAThe effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutolAm J Respir Crit Care Med19991595 Pt 1 1580 158410228130
   PubMed Web of Science ®Google Scholar
• TolmanKGFonsecaVDalpiazATanMHSpectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver diseaseDiabetes Care2007303 734 74317327353
   PubMed Web of Science ®Google Scholar
• MerrellMDCherringtonNJDrug metabolism alterations in nonalcoholic fatty liver diseaseDrug Metab Rev2011433 317 33421612324
   PubMed Web of Science ®Google Scholar
• RodighieroVEffects of liver disease on pharmacokinetics. An updateClin Pharmacokinet1999375 399 43110589374
   PubMed Web of Science ®Google Scholar
• LiamisGLiberopoulosEBarkasFElisafMDiabetes mellitus and electrolyte disordersWorld J Clin Cases2014210 488 49625325058
   PubMed Web of Science ®Google Scholar
• TakasuNYamadaTMiuraHRifampicin-induced early phase hyperglycemia in humansAm Rev Respir Dis19821251 23 277039435
   PubMed Web of Science ®Google Scholar
• AtkinSLMassonEABodmerCWWalkerBAWhiteMCIncreased insulin requirement in a patient with Type 1 diabetes on rifampicinDiabet Med1993104 3928508626
   PubMed Web of Science ®Google Scholar
• Bromocriptine^® (bromocriptine mesylate) tablets [prescribing information]TakeleyMeda Pharmaceuticals2012
   Google Scholar
• AlsultanAPeloquinCATherapeutic drug monitoring in the treatment of tuberculosis: an updateDrugs2014748 839 85424846578
   PubMed Web of Science ®Google Scholar
• PeloquinCATherapeutic drug monitoring in the treatment of tuberculosisDrugs20026215 2169 218312381217
   PubMed Web of Science ®Google Scholar
• BabalikAUlusIHBakirciNPlasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitusAntimicrob Agents Chemother20135711 5740 574223979746
   PubMed Web of Science ®Google Scholar
• HeysellSKMooreJLStaleyDDodgeDHouptEREarly therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USATuberc Res Treat20132013 12972324349775
   PubMedGoogle Scholar
• GumboTLouieADezielMRConcentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampinAntimicrob Agents Chemother20075111 3781 378817724157
   PubMed Web of Science ®Google Scholar
• JayaramRGaonkarSKaurPPharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosisAntimicrob Agents Chemother2003477 2118 212412821456
   PubMed Web of Science ®Google Scholar
• DooleyKFlexnerCHackmanJRepeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrationsAntimicrob Agents Chemother20085211 4037 404218765687
   PubMed Web of Science ®Google Scholar
• HeysellSKMooreJLKellerSJHouptERTherapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USAEmerg Infect Dis20101610 1546 155320875279
   PubMed Web of Science ®Google Scholar
• KwaraACaoLYangHFactors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearancePharmacotherapy2014343 265 27124420746
   PubMed Web of Science ®Google Scholar
• MotaLAl-EfraijKCampbellJRCookVJMarraFJohnstonJTherapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysisInt J Tuberc Lung Dis2016206 819 82627155187
   PubMed Web of Science ®Google Scholar
• AlkababYKellerSDodgeDHouptEStaleyDHeysellSEarly interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USABMC Infect Dis2017171 12528166721
   PubMed Web of Science ®Google Scholar